Thalidomide for the treatment of patients with myelodysplastic syndromes

被引:0
|
作者
C Strupp
U Germing
M Aivado
E Misgeld
R Haas
N Gattermann
机构
[1] Oncology and Clinical Immunology,Department of Hematology
[2] Heinrich-Heine-University,undefined
来源
Leukemia | 2002年 / 16卷
关键词
myelodysplastic syndromes; angiogenesis; thalidomide; TNF-α;
D O I
暂无
中图分类号
学科分类号
摘要
We examined the efficacy of thalidomide in 34 patients with myelodysplastic syndromes (MDS): five RAEB-T, four RAEB, three CMML, six RARS, and 16 RA. Patients belonged to the following cytogenetic groups: 15 complex abnormal karyotypes, 12 normal karyotypes, four cases with 5q− as sole anomaly and three single aberrations. The median thalidomide dose was 400 mg/day (25/34 patients). Four patients discontinued the study after less than 5 weeks, because of fatigue (three) or skin rash (one). One patient died of heart failure after 4 weeks. In the remaining 29 patients (median follow-up: 13 months), treatment responses were classified according to the IWG criteria. Six patients (four RA, two CMML) showed progressive disease (five with transformation into AML) and four patients showed stable disease. Hematological improvement (HI) was observed in 19 patients. Nine of the responders (three RA, one RARS, two RAEB, three RAEB-T) achieved partial remission with granulocytes ⩾1500/μl, Hb > 11 g/dl and platelets ⩾100 000/μl. Four patients (one RARS, one CMML, one RAEB, one RAEB-T) had a major response, with platelet and RBC transfusion independence. Six patients (five RA, one RARS) showed minor responses (three HI-E, two HI-E+HI-P, one HI-E+HI-N). Hematological improvement occurred after a median of 2 months of thalidomide treatment. Two patients (RAEB-T) relapsed after a partial remission lasting 8 and 16 months, respectively. In summary, a therapeutic benefit was achieved in 19 of 34 study patients (56%).
引用
收藏
页码:1 / 6
页数:5
相关论文
共 50 条
  • [1] Thalidomide for the treatment of patients with myelodysplastic syndromes
    Strupp, C
    Germing, U
    Aivado, M
    Misgeld, E
    Haas, R
    Gattermann, N
    [J]. LEUKEMIA, 2002, 16 (01) : 1 - 6
  • [2] Treatment of myelodysplastic syndromes with azacitidine and thalidomide
    Kenealy, M. K.
    Seymour, J. F.
    [J]. LEUKEMIA RESEARCH, 2007, 31 : S7 - S8
  • [3] Combination of thalidomide and Enbrel for the treatment of patients with myelodysplastic syndromes (MDS).
    Raza, A
    Dutt, D
    Lisak, L
    Dean, L
    Fantroy, L
    Gezer, S
    Syed, E
    Goldberg, C
    Loew, J
    Hsu, WT
    Venugopal, P
    [J]. BLOOD, 2001, 98 (11) : 273B - 274B
  • [4] Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes
    Musto, P
    Falcone, A
    Sanpaolo, G
    Bodenizza, C
    [J]. LEUKEMIA RESEARCH, 2006, 30 (04) : 385 - 388
  • [5] Cyclosporine a without or with thalidomide for the treatment of patients with Myelodysplastic syndromes.
    Xiao, Zhijian
    Xu, Zefeng
    Wang, Jianxiang
    Hao, Yushu
    [J]. BLOOD, 2007, 110 (11) : 222B - 222B
  • [6] Thalidomide in myelodysplastic syndromes
    Zorat, F
    Pozzato, G
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2002, 56 (01) : 20 - 30
  • [7] The clinical and biological effects of thalidomide in patients with myelodysplastic syndromes
    Zorat, F
    Shetty, V
    Dutt, D
    Lisak, L
    Nascimben, F
    Allampallam, K
    Dar, S
    York, A
    Gezer, S
    Venugopal, P
    Raza, A
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (04) : 881 - 894
  • [8] Delayed responses to thalidomide in patients with myelodysplastic syndromes.
    Lisak, LA
    Little, L
    Dean, L
    Ekbal, M
    duRandt, M
    Hussain, M
    Kaistha, V
    Raza, A
    [J]. BLOOD, 2000, 96 (11) : 261B - 261B
  • [9] Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study
    Xiao, Zhijian
    Xu, Zefeng
    Zhang, Yue
    Qin, Tiejun
    Zhang, Hongli
    Fang, Liwei
    [J]. LEUKEMIA RESEARCH, 2011, 35 (01) : 61 - 65
  • [10] Improvement in cytopenias of patients with myelodysplastic syndromes (MDS) in response to thalidomide
    Raza, A
    Lisak, L
    Little, L
    Andrews, C
    Meyer, P
    Ekbal, M
    Venugopal, P
    [J]. EXPERIMENTAL HEMATOLOGY, 2000, 28 (07) : 103 - 104